<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Approximately 30-40% of patients with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> (BE) patients manifest abnormal oesophageal pH profiles despite <z:chebi fb="0" ids="49200">proton pump inhibitor</z:chebi> (<z:chebi fb="4" ids="53266">PPI</z:chebi>) therapy </plain></SENT>
<SENT sid="1" pm="."><plain>AIM: To determine control of <z:e sem="disease" ids="C0017168,C0559234" disease_type="Disease or Syndrome;Finding" abbrv="">oesophageal reflux</z:e> using Bravo pH monitoring in patients BE on <z:chebi fb="14" ids="7772">omeprazole</z:chebi>-<z:chebi fb="17" ids="32139">sodium bicarbonate</z:chebi> oral suspension powder (Ome-NaBic) 40 mg twice daily </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Initial pH monitoring off <z:chebi fb="4" ids="53266">PPI</z:chebi> for 1 week was performed </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients underwent repeat pH testing on Ome-NaBic administered before breakfast and at bedtime after 21-28 days of therapy depending upon the prior <z:chebi fb="4" ids="53266">PPI</z:chebi> therapy </plain></SENT>
<SENT sid="4" pm="."><plain>The goal was to enroll 30 subjects, however, the trial was terminated prematurely when the sponsor lost financing due to a change in business strategy </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: A total of 88 patients responded to the study invitation, 27 patients signed informed consent, and 21 patients underwent pH testing of <z:chebi fb="4" ids="53266">PPI</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>A total of 15 patients completed the protocol (13 men, 2 women) </plain></SENT>
<SENT sid="7" pm="."><plain>Demographic information for patients completing at least one Bravo study included a mean (±s.d.) age 62 ± 9 years; body mass index 31 ± 8 kg/m(2) (range 23-48); mean BE length of 2.6 ± 2 cm; 9 (43%) patients with long segment BE </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> (100%) patients demonstrated normalisation of supine pH on both days of Ome-NaBic therapy </plain></SENT>
<SENT sid="9" pm="."><plain>One patient (6%) demonstrated abnormal upright reflux on the second day of monitoring on Ome-NaBic therapy; <z:hpo ids='HP_0000001'>all</z:hpo> the other patients demonstrated <z:mpath ids='MPATH_458'>normal</z:mpath> pH scores on therapy </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Administration of twice daily Ome-NaBic demonstrated control of nocturnal <z:e sem="disease" ids="C0017168,C0559234" disease_type="Disease or Syndrome;Finding" abbrv="">oesophageal reflux</z:e> in 100% of patients with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e>, and complete control of oesophageal pH during 97% of the 24-h recording periods </plain></SENT>
</text></document>